| Vernalis (R&D) Limited Patent applications |
| Patent application number | Title | Published |
|---|
| 20110105551 | Analgesics for nasal administration - An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, C | 05-05-2011 |
| 20100105651 | ANTAGONISTS OF SNS SODIUM CHANNELS - Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R | 04-29-2010 |
| 20100041624 | Buprenorphine formulations for intranasal delivery - Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C | 02-18-2010 |
| 20090023697 | ANALGESIA METHOD - Opioid tolerance is reduced by treating the patient with a neurosteroid of formula (I) wherein R1 is H or methyl; R2 is OH and R3 is H, or R2 and R3 taken together are O; R4 is H or methyl; R5 and R6 are each H, or R5 and R5 taken together are O; R7 is H or methyl; and R8 is H, OH, —OC(═O)CH3, SH, —SC(═O)CH3, Cl, Br or F. | 01-22-2009 |
